Emergent BioSolutions Inc. (NYSE:EBS) Q2 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Q2 2023 Emergent BioSolutions Inc. Earnings Conference Call. [Operator Instructions].
Emergent Biosolutions Inc. (EBS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Millennium Management Israel Englander | 1,282,274 | $9,424,714 | +216% | 0% |
| 2. | D E Shaw D. E. Shaw | 977,917 | $7,187,690 | -29% | 0% |
| 3. | Two Sigma Advisors John Overdeck And David Siegel | 716,900 | $5,269,215 | +47% | 0.01% |
| 4. | Citadel Investment Group Ken Griffin | 621,403 | $4,567,312 | +43% | 0% |
| 5. | GLG Partners Noam Gottesman | 449,955 | $3,307,169 | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $37.46 | 3,000 | Officer | 39,919 | 2021-11-15 | Filing | |
| $27.08 | 98 | Officer | 41,444 | 2015-06-01 | Filing | |
| $19.08 | 749 | Officer, Director | 103,373 | 2013-11-30 | Filing | |
| $12.07 | 800 | Officer, Director | 96,011 | 2013-05-31 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.35 | 1,830 | Director | 49,971 | 2023-06-02 | Filing | |
| $8.38 | 1,700 | Director | 51,801 | 2023-05-25 | Filing | |
| $11.94 | 1,912 | Director | 19,837 | 2022-11-25 | Filing | |
| $31.52 | 1,173 | Director | 19,654 | 2022-06-09 | Filing | |
| $35.53 | 1,996 | Director | 12,381 | 2022-05-24 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,231,728 | $67,853,201 | 0% | |
| 2. | 6,794,144 | $49,936,958 | 0% | |
| 3. | 4,342,342 | $31,916,214 | 0% | |
| 4. | 1,489,585 | $10,949,156 | 0% | |
| 5. | 1,234,447 | $9,073,185 | 0.05% |
News See All
Emergent BioSolutions Inc. (NYSE:EBS) Q1 2023 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Emergent BioSolutions First Quarter 2020 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Emergent BioSolutions Inc. (NYSE:EBS) Q4 2022 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Emergent BioSolutions Fourth Quarter and Full Year 2022 Financial Results Conference Call.
10 Best Stocks to Buy According to Yale Finance Professor
In this article, we will be taking a look at the top 10 stocks to buy according to Roger Ibbotson's Zebra Capital.
5 Healthcare and Biotech Stocks to Buy Amid Monkeypox Threat
In this article, we will look at 5 healthcare and biotech stocks to buy amid the monkeypox threat.
10 Stocks to Sell According to Jinghua Yan's TwinBeech Capital
In this article, we discuss 10 stocks to sell according to Jinghua Yan's TwinBeech Capital.
Should Consider Disposing Your Emergent BioSolutions (EBS) Shares?
Carillon Tower Advisers, an investment management firm, published its “Carillon Eagle Small Cap Growth Fund” second quarter 2021 investor letter – a copy of which can be downloaded here.
Should You Be Tempted To ‘Sell’ Emergent Biosolutions (EBS) Stock?
Baron Discovery Fund recently published its second-quarter commentary – a copy of which can be downloaded here.
Here's Why Emergent BioSolutions (EBS) Became One of Carillon's Worst Securities
Carillon Tower Advisers, an investment management firm, published its fourth quarter 2020 “Carillon Eagle Small Cap Growth Fund” investor letter – a copy of which can be downloaded here.
Is Emergent Biosolutions (EBS) Stock a Buy For 2021?
Baron Discovery Fund recently published its fourth-quarter commentary – a copy of which can be downloaded here.
Billionaire Hedge Funds
